Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
My thought are: Quiet till the FDA Meeting in up to 45 days. Than, RNS on the outcome and capital increase. We can reach 15p at best? Than wait another 6m for approval and hope we are in the 80% who gets finally approved. Dead money for quiet long, but with chance of 4folder if approved. Has now the second time problems..
missed Petchs question on the salery ...
When the FDA first raised the issue, the went back with more details and had obivously 3 liver experts as well supporting Motif. But that wasnt enough...
Guess, they dont know exactly, what the FDA wants in detail...
how can you answer this question, without having the FDA meeting done?
how can you answer this question, without having the FDA meeting done?
Ian, thats right, but all other countries will most likely follow the FDA decission as well. We have to wait, what the FDA says, Motif should change or provide. Everybody knows, that a capital increase will come. So this should be nearly priced in already. Even a bigger one. I think our board has a bright knowledge and they should be able to get the cow from the ice. It is risky, but will increase my holding here. Did trust 4 years in the management at higher levels, why should I change now, even if Im pissed sometimes.
if you are not getting an approval with the FDA, it will be very difficult in other countries as well.
who told last week, Motif will meet the FDA in two weeks already??? 3mln cash and 7.7mln debt left. Fantastic result. sorry, that Im so negative. Will stop writing now and take a coffee..
what happens if Invesco and Co continue to sell their shares? Surprised Hercules has no faith in Motif to help them repay. Instead they want their money back. If it is just a small change to get the apporval, they could have waited and helped. Im even more pissed now...
5p is only a bargain, if you are sure, they get approved. 2 times problems with Iclaprim and propably 12months waiting period till it gets approved finally. In the meantime a capital increase of at least 20mln, because Hercules needs to get paid back? So honestly, and its AIM listed, where do you think this one trades? They are the experts and in 2008 the FDA had already concerns about liver safety, due to an imbalance in ALT/AST. Which didnt happen now at Motif, but the FDA still raises a flag and the datas from Motif were not enough. So they change the NDA and start from the beginning with another label? Not easy to sell after to hospitals?? I still hold all my stock, but if we trade in the direction of 20p, Im out and watch from the sideline.
Fund raise. In the meetings with GL, he always mentioned, to try and not to do raises below 50p, or to avoid dilution with debt or grants. What happened? Some capital increases at 30-35p. So forgett your increase at 20p, it will not happen. If they are lucky, would expect 10-15p.
HI Coldfish, thanks for your answer. Thought Iclaprims advantage is no sideffect on liver, renal etc. . For systic fibrosis this is highly important as well.. as a selling argument, I think it is really important. So lets wait the outcome of the meeting and that we dont have to wait 12 months to get the approval.
Lets hope the FDA meeting will go ok and they can fix it with a small study. Im not an expert, but fear, that a lablechange further reduces the chances for Iclaprim in the future. What do you think?
Hi Thoths, what do you think now about the market potential?
The BOD is forced by law to give such an statement about the financials. Guess SEC rule??
Exactly! That doesnt fit in the picture, that nearly all big pharmaplayers left the field. Iclaprim has now the second time problems getting to the market. That makes partnershipdeals not easy...
Yes, you are right, the marketcap is 30mln. Would expect Motif to trade marketcapwise in a range of 20-50mln for the next few weeks..
To use Iclaprim against cystic fibrosis, might be difficult or its gone now. Who knows, we have to wait for the outcome of the FDA Meeting.
Even, if toths is right and the market is difficult, isnt the current marketcap clearly Top low? 15 mln, when you may have only a labeling issue? Iclaprim needs to do only 5mln sales to justify that marketcap and i am sure we will do a bit more...